Over the past years, several lines of evidence support a therapeutic potential of Cannabis
derivatives and in particular phytocannabinoids. Δ 9-THC and cannabidiol (CBD) are the …

Introduction: Cannabidiol (CBD) as Epidiolex®(GW Pharmaceuticals) was recently
approved by the US Food and Drug Administration (FDA) to treat rare forms of epilepsy in …

Apart from having been used and misused for at least four millennia for, among others,
recreational and medicinal purposes, the cannabis plant and its most peculiar chemical …

Cannabis has a long history of anecdotal medicinal use and limited licensed medicinal use.
Until recently, alleged clinical effects from anecdotal reports and the use of licensed …

First isolated from Cannabis in 1940 by Roger Adams, the structure of CBD was not
completely elucidated until 1963. Subsequent studies resulted in the pronouncement that …

Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from Cannabis
sativa. It has possible therapeutic effects over a broad range of neuropsychiatric disorders …

Cannabidiol (CBD) is a major non-psychotropic phytocannabinoid that attracted a great
attention for its therapeutic potential against different pathologies including skin diseases …

Though there is limited research confirming the purported topical benefits of cannabinoids, it
is certain that cutaneous biology is modulated by the human endocannabinoid system …

Alzheimer's disease (AD) is a neurodegenerative disease, in which the primary etiology
remains unknown. AD presents amyloid beta (Aβ) protein aggregation and neurofibrillary …

Cannabidiol (CBD) is a phytocannabinoid with therapeutic properties for numerous
disorders exerted through molecular mechanisms that are yet to be completely identified …